TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06390891

Intervention type: OTHER
Intervention: Persons with pancreatic resection in a hospital with at least 50 pancreatic resections annually (observational),
Description: Persons that have undergone a pancreatic resection at a hospital with at least 50 pancreatic resections annually (observational)

Intervention type: OTHER
Intervention: Persons with pancreatic resection in a hospital not performing at least 50 pancreatic resections annually (observational),
Description: Persons that have undergone a pancreatic resection at a hospital with not at least 50 pancreatic resections annually (observational)
Study: NCT04374708

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: fMRI: body morph test and neurocognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: fMRI: body morph test and neurocognitive testing

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: fMRI: body morph test and neurocognitive testing
Study: NCT03407924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study: NCT02868216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: anger management training
Study: NCT01167426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate 20 mg/0.5 mL
Description: 20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate 20 mg/0.5 mL
Description: 20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
Study: NCT01930019

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)
Study: NCT02993471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Cocktail
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT02638415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Description: Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails.
Study: NCT03837821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 200 mg oral, every 12 hours
Study: NCT04041388

Intervention type: OTHER
Group type: OTHER
Intervention: Conebeam CT
Description: medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
Study: NCT01433458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLX030A
Description: RLX030 is administered as a continuous 24 hour infusion
Study: NCT03331159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoBone
Description: Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Homologous Bone
Description: Cage was filled with homologous bone
Study: NCT01749358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Monitoring
Description: This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
Study: NCT03798379

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
Study: NCT04473716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxcel
Description: Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy/chemoradiotherapy
Description: Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
Study: NCT03899649

Intervention type: DRUG
Intervention: SOC
Description: Standard of Care treatment

Intervention type: DRUG
Intervention: SOC
Description: Standard of Care treatment

Intervention type: DEVICE
Intervention: NanoKnife System
Description: Irreversible Electroporation
Study: NCT04451928

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum sample analysis
Description: Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum sample analysis
Description: Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
Study: NCT02638519

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Proton fMRI
Description: Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Proton fMRI
Description: Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Xenon-129 fMRI
Description: HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Xenon-129 fMRI
Description: HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon-129
Description: Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized Xenon-129
Description: Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.

Intervention type: DEVICE
Group type: OTHER
Intervention: 1H-129Xe Dual-Tuned Quadrature Head Coil
Description: A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
Study: NCT02638415

Intervention type: OTHER
Group type: OTHER
Intervention: routine therapy
Description: Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
Study: NCT00677131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral education provided by the pharmacist
Description: Oral education provided by the pharmacist
Study: NCT00956969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Awareness and Expression
Description: Teaches patients to recognize, experience, and express emotions
Study: NCT02638415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
Study: NCT00956969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Teaches patients relaxation training
Study: NCT00456248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infergen and ribavirin
Description: Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
Study: NCT02769104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole (Aromatase Inhibitors)
Description: Letrozole (Aromatase Inhibitors) for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC*4-T*4
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Study: NCT02769104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC*4-T*4
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Study: NCT01779960

Intervention type: OTHER
Intervention: Londrina
Description: Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
Study: NCT00456248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infergen and ribavirin
Description: Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
Study: NCT02638415

Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol
Description: Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
Study: NCT04531488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Powered Mobility Training Simulator
Description: Two groups of participants- 18 in each- were provided with either a simulator or powered wheelchair. Both groups were tested at baseline for powered mobility level. Both groups the practiced at home or school for 12 weeks, 4 times a week for at least 20 minutes. Both groups returned and underwent another evaluation to assess powered mobility level after 12 weeks of practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with Powered Wheel Chair
Description: Training with Powered Wheel Chair
Study: NCT00604006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg tablets (placed in capsules for blinding) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (lactose in capsules for blinding) once daily
Study: NCT03985072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andes-1537 for Injection
Description: Andes-1537 administered subcutaneously five days per week.
Study: NCT02882048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NADA Protocol
Description: NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management
Description: Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
Study: NCT04472364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoPill Acute ®
Description: Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
Study: NCT04747483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extension Oriented Treatment Approach
Description: The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland.
Study: NCT02882048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication management
Description: Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
Study: NCT02410538

Intervention type: OTHER
Intervention: list of FAQ

Intervention type: OTHER
Intervention: list of FAQ
Study: NCT00973141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study: NCT04747483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EOTA+ Traction
Description: Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks.
Study: NCT04022174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate dosage training of action Observation and Motor imagery
Description: Motor imagery and action observation of orofacial exercises with moderate dosage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dosage training of action observation and motor imagery
Description: Motor imagery and action observation of the orofacial exercises with intensive dosage
Study: NCT01779960

Intervention type: OTHER
Intervention: Leuven
Description: Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
Study: NCT04022174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intensive dosage orofacial exercises
Description: Orofacial exercises with high intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate dosage orofacial exercises
Description: Orofacial exercises with moderate intensity
Study: NCT03523832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib and Pregabaline
Description: Single dose versus repetition dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib and Pregabaline
Description: Single dose versus repetition dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03631862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Regimen
Description: CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Regimen
Description: CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
Study: NCT00973141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
Study: NCT03797937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: MRI scanner
Study: NCT01993082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Intervention
Description: For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage.
Study: NCT00973141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study: NCT04608058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital storytelling training
Description: The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine training
Description: The control group received the clinics' routine training include face to face class education.
Study: NCT00973141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).